Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant bevacizumab and temozolomide for newly diagnosed malignant glioma
jRCT1031180233Phase 2Completed
- Start
- Mar 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab and temozolomide in malignant glioma and glioblastoma (GBM). Primary endpoint: Progression-free survival. Started Mar 2017; status: completed.
02
Drugs
bevacizumabtemozolomide
03
Conditions
malignant gliomaglioblastoma (GBM)
Beyond the preview
Go deeper on jRCT1031180233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031180233.